点击图片查看原图
全国高等学校教材/口腔正畸专科教程
临床肺部感染病学【刘朝晖 主编】
王海燕《肾脏病学》第3版医学书店优惠
通过天津市市场和质量监督管理委员会认证 
《肿瘤放射治疗靶区勾
Kirklin/Barratt-Boye
喉部解剖与手术指南
图解心脏康复指南
《超声心动图病例精粹
《美式整脊技术:原理
华盛顿危重病医学手册
《坎贝尔骨科手术学》| 数量： | 10 |
| 先款后货： | Right |
| 页数： | 2022 |
| ISBN： | 9787543331792 |
| 印刷次数： | 1 |
| 邮费承担方： | 买方 |
| 语种： | 英文 |
| 出版时间： | 20130101 |
| 字数： | 4200千字 |
| 纸张类型： | 80g铜版纸 |
| 原价： | 680 |
| 版次： | 第9版 |
| 包装： | 精装 |
| 印刷时间： | 20130101 |
| 开本： | 16 |
| 印次： | 1 |
| 邮费： | 30 |
官方链接
www.tsttpc.com
http://v.youku.com/v_show/id_XNTE3MzMyNjUy.html
图书描述
《Braunwald心脏病学:心血管内科学教科书(英文影印版•第9版)(套装上下册)》分为10部分，共94章，除了继续保持前几版的风格和传统，内容覆盖心脏病学领域的各个部分，注重介绍疾病预防与诊治的最新进展之外，还对全书进行了全面的更新。在之前版本基础上新增了9章，而且有24章增加了新的内容。本版着重阐述了心脏病学最前沿的知识，包括分子成像、血管内超声、心血管再生和组织工程、通过器械检测心衰程度及心衰的器械治疗、房颤的治疗、结构性心脏疾病、Chagasic心脏病、心血管医学伦理学、临床试验设计和执行等研究热点。此外《Braunwald心脏病学:心血管内科学教科书(英文影印版•第9版)(套装上下册)》还对美国心脏病学会心血管疾病的最新指南进行了总结，并附有约2500幅精美图片和600张表格。为广大心血管专业医师、内科医师及医学生提供了最权威的指导和最佳的可行性方法，是学习心血管医学不可或缺的学习工具和案头参考书！
赠送全彩互动式多媒体光盘(上、下两卷+单盘)。
The results of published studies on the efficacy of antiarrhythmic drugs for AF suggest that all of the available drugs except amiodarone have similar efficacy and are associated with a 50% to 60% reduction in the odds of recurrent AF during 1 year of treatment.29 The one drug that stands out as having higher efficacy than the others is amiodarone. In studies that directly compared amiodarone with sotalol or class I drugs, amiodarone was 60% to 70% more effective in suppressing AF. However, because of the risk of organ toxicity, amiodarone is not appropriate first-line drug therapy for most categories of patients with AF. Because their efficacy is in the same general range, the selection of an antiarrhythmic drug to prevent AF often is dictated by the issues of safety and side effects.
Ventricular proarrhythmia from class IA agents (quinidine, procainamide, disopyramide) and class III agents (sotalol, dofetilide, drone-darone, amiodarone) is manifested as QT prolongation and polymorphic ventricular tachycardia (torsades de pointes). Risk factors for this type of proarrhythmia include female gender, left ventricular dysfunction, and hypokalemia.The risk of torsades de pointes appears to be much lower with dronedarone and amiodarone than with the other class Ill drugs.The ventricular proarrhythmia from class IC agents (flecainide and propafenone) is manifested as monomorphic ventricular tachycardia, sometimes associated with widening of the QRS complex during sinus rhythm but not QT prolongation. Published studies indicate that the drugs most likely to result in ventricular proarrhythmia are quinidine, fiecainide, sotalol, and dofetilide. In controlled studies, these agents increased the risk of ventricular tachycardia by a factor of 2 to 6.
Adverse drug events resulting in discontinuation of drug therapy are fairly common with rhythm-control drugs.Withdrawal due to adverse effects was most common with quinidine, disopyramide, flecainide,sotalol, and amiodarone.29 A review of studies in which 32 treatment arms received an antiarrhythmic drug for AF found that 10.4% of patients discontinued drug therapy because of an adverse drug event,most commonly gastrointestinal side effects and neuropathy.
The best options for drug therapy to suppress AF depend on the patient's comorbidities. In patients with lone AF or minimal heart disease (e.g., mild left ventricular hypertrophy), flecainide, propafenone, sotalol, and dronedarone are reasonable first-line drugs, and amiodarone and dofetilide can be considered if the first-line agents are ineffective or not tolerated. In patients with substantial left ventricular hypertrophy (left ventricutar wall thickness >13 mm), the hypertrophy may heighten the risk of ventricular proarrhythmia, and the safest choice for drug therapy is amiodarone. In patients with coronary artery disease, several of the class I drugs have been found toincrease the risk of death, and the safest first-line options are dofetilide, sotalol, and dronedarone, with amiodarone reserved for use asa second-line agent. In patients with heart failure, several antiarrhythmic drugs have been associated with increased mortality,and the onlytwo drugs known to have a neutral effect on survival are amiodaroroneand dofetilide (see Chap. 37).
赠送全彩互动式多媒体光盘(上、下两卷+单盘)。
商品描述
编辑推荐
《Braunwald心脏病学:心血管内科学教科书(英文影印版•第9版)(套装上下册)》编辑推荐：原版影印，附赠含原书彩图的光盘，使广大心血管医生更好地领略这部经典巨著的风采，了解和掌握当今国际上最权威、最前沿的心脏病学专业知识和信息，提高临床专业知识和专业技能，从容地面对临床的各种挑战！
《Braunwald心脏病学:心血管内科学教科书(英文影印版•第9版)(套装上下册)》由美国哈佛大学医学院的著名的心血管学专家Eugene Braunwald教授主编，自1980年问世以来，一直是心血管病学领域最为重要的大型教材。目前已出版到第9版。人民卫生出版社曾翻译过该书的第7版，受到很多心血管医生的好评。目前考虑到该书的学术价值、市场需求，以及内容的大量更新，特引进此书的原版影印版来满足国内广大读者的需求。
《Braunwald心脏病学:心血管内科学教科书(英文影印版•第9版)(套装上下册)》由美国哈佛大学医学院的著名的心血管学专家Eugene Braunwald教授主编，自1980年问世以来，一直是心血管病学领域最为重要的大型教材。目前已出版到第9版。人民卫生出版社曾翻译过该书的第7版，受到很多心血管医生的好评。目前考虑到该书的学术价值、市场需求，以及内容的大量更新，特引进此书的原版影印版来满足国内广大读者的需求。
作者简介
作者：（美国）Eugene Braunwald 编者：（美国）罗伯特•O•波诺 （美国）道格拉斯•P•兹普 （美国）彼得•利贝 （美国）道格拉斯•L•曼
Eugene Braunwald，教授，美国哈佛大学医学院的著名心血管学专家，心脏病学泰斗，他主编的心脏病学和哈里森内科学是全世界心血管医生的圣经。
罗伯特•0•波诺教授，美国芝加哥西北大学Feinberg医学院心脏中心主任，医学部副主席，美国心脏学会主席。道格拉斯•L•曼教授，美国圣 路易斯华盛顿大学Barnes jewish医院心脏科主任，细胞生物和生理医学教授。道格拉斯•P•兹普教授，美国印第安纳大学医学院Krannert心脏研究所和心脏中心名誉主任。 彼得•利贝教授，美国布莱根妇女医院心血管科主任，哈佛医学院医学教授。
霍勇（专家推荐），北京大学第一医院，心内科及心脏中心主任，主任医师，教授，博士生导师，中华医学会心血管病学分会候选主任委员、中国医师协会心血管内科医师分会副会长，《中国介入心脏病学杂志》主编，中华医学会心血管介入治疗培训中心主任。
Eugene Braunwald，教授，美国哈佛大学医学院的著名心血管学专家，心脏病学泰斗，他主编的心脏病学和哈里森内科学是全世界心血管医生的圣经。
罗伯特•0•波诺教授，美国芝加哥西北大学Feinberg医学院心脏中心主任，医学部副主席，美国心脏学会主席。道格拉斯•L•曼教授，美国圣 路易斯华盛顿大学Barnes jewish医院心脏科主任，细胞生物和生理医学教授。道格拉斯•P•兹普教授，美国印第安纳大学医学院Krannert心脏研究所和心脏中心名誉主任。 彼得•利贝教授，美国布莱根妇女医院心血管科主任，哈佛医学院医学教授。
霍勇（专家推荐），北京大学第一医院，心内科及心脏中心主任，主任医师，教授，博士生导师，中华医学会心血管病学分会候选主任委员、中国医师协会心血管内科医师分会副会长，《中国介入心脏病学杂志》主编，中华医学会心血管介入治疗培训中心主任。
目录
《Braunwald心脏病学：心血管内科学教科书（上册）》目录：
PART Ⅰ FUNDAMENTALS OF CARDIOVASCULAF DISEASE
CHAPTER1 Global Burden of Cardiovascular Disease 1
CHAPTER2 Heart Disease in Varied Populations 21
CHAPTER3 Ethics in Cardiovascular Medicine 30
CHAPTER4 Clinical Decision Making in Cardiology 35
CHAPTER5 Measurement and Improvement of Quality of Cardiovascular Care 42
CHAPTER6 Design and Conduct of Clinical Trials 49
PART Ⅱ MOLECULAR BIOLOGY AND GENETICS
CHAPTER7 Principles of Cardiovascular Molecular Biology and Genetics 57
CHAPTER8 Inherited Causes of Cardiovascular Disease 70
CHAPTER 9 Genetics of Cardiac Arrhythmias 81
CHAPTER10 Principles of Drug Therapy 91 Dan M. Roden
CHAPTER 11 Cardiovascular Regeneration and Tissue Engineering 99
PART Ⅲ EVALUATION OF THE PATIENT
CHAPTER12 The History and Physical Examination: An Evidence-Based Approach 107
CHAPTER13 Electrocardiography 126
Guidelines: Electrocardiography 165
CHAPTER14 Exercise Stress Testing 168
Guidelines: Exercise StressTesting 192
CHAPTER15 Echocardiography 200
Appropriate Use Criteria: Echocardiography 270
CHAPTER16 The Chest Radiograph in Cardiovascular Disease 277
CHAPTER17 Nudear Cardiology 293
Appropriate Use Criteria: Nuclear Cardiology 336
CHAPTER18 Cardiovascular Magnetic Resonance Imaging 340
Appropriate Use Criteria: Cardiovascular Magnetic Resonance 359
CHAPTER19 Cardiac Computed Tomography 362
Appropriate Use Criteria: Cardiac Computed Tomography 379
CHAPTER20 Cardiac Catheterization 383
……
PART Ⅳ HEART FAILURE
PART Ⅴ ARRHYTHMIAS, SUDDEN DEATH, AND SYNCOPE
PART Ⅵ PREVENTIVE CARDIOLOGY
PART Ⅶ ATHEROSCLERoTlC CARDlOVASCULAR DIASEASE
PART Ⅷ DISEASES OF THE HEART, PERICARDIUM，AND PULMONARY VASCULATURE BED
PART Ⅹ CARDIOVASCULAR DISEASE AND DISORDERS OF OTHER ORGANS
……
《Braunwald心脏病学：心血管内科学教科书（下册）》
PART Ⅰ FUNDAMENTALS OF CARDIOVASCULAF DISEASE
CHAPTER1 Global Burden of Cardiovascular Disease 1
CHAPTER2 Heart Disease in Varied Populations 21
CHAPTER3 Ethics in Cardiovascular Medicine 30
CHAPTER4 Clinical Decision Making in Cardiology 35
CHAPTER5 Measurement and Improvement of Quality of Cardiovascular Care 42
CHAPTER6 Design and Conduct of Clinical Trials 49
PART Ⅱ MOLECULAR BIOLOGY AND GENETICS
CHAPTER7 Principles of Cardiovascular Molecular Biology and Genetics 57
CHAPTER8 Inherited Causes of Cardiovascular Disease 70
CHAPTER 9 Genetics of Cardiac Arrhythmias 81
CHAPTER10 Principles of Drug Therapy 91 Dan M. Roden
CHAPTER 11 Cardiovascular Regeneration and Tissue Engineering 99
PART Ⅲ EVALUATION OF THE PATIENT
CHAPTER12 The History and Physical Examination: An Evidence-Based Approach 107
CHAPTER13 Electrocardiography 126
Guidelines: Electrocardiography 165
CHAPTER14 Exercise Stress Testing 168
Guidelines: Exercise StressTesting 192
CHAPTER15 Echocardiography 200
Appropriate Use Criteria: Echocardiography 270
CHAPTER16 The Chest Radiograph in Cardiovascular Disease 277
CHAPTER17 Nudear Cardiology 293
Appropriate Use Criteria: Nuclear Cardiology 336
CHAPTER18 Cardiovascular Magnetic Resonance Imaging 340
Appropriate Use Criteria: Cardiovascular Magnetic Resonance 359
CHAPTER19 Cardiac Computed Tomography 362
Appropriate Use Criteria: Cardiac Computed Tomography 379
CHAPTER20 Cardiac Catheterization 383
……
PART Ⅳ HEART FAILURE
PART Ⅴ ARRHYTHMIAS, SUDDEN DEATH, AND SYNCOPE
PART Ⅵ PREVENTIVE CARDIOLOGY
PART Ⅶ ATHEROSCLERoTlC CARDlOVASCULAR DIASEASE
PART Ⅷ DISEASES OF THE HEART, PERICARDIUM，AND PULMONARY VASCULATURE BED
PART Ⅹ CARDIOVASCULAR DISEASE AND DISORDERS OF OTHER ORGANS
……
《Braunwald心脏病学：心血管内科学教科书（下册）》
文摘
Pharmacologic Rhythm ControlThe results of published studies on the efficacy of antiarrhythmic drugs for AF suggest that all of the available drugs except amiodarone have similar efficacy and are associated with a 50% to 60% reduction in the odds of recurrent AF during 1 year of treatment.29 The one drug that stands out as having higher efficacy than the others is amiodarone. In studies that directly compared amiodarone with sotalol or class I drugs, amiodarone was 60% to 70% more effective in suppressing AF. However, because of the risk of organ toxicity, amiodarone is not appropriate first-line drug therapy for most categories of patients with AF. Because their efficacy is in the same general range, the selection of an antiarrhythmic drug to prevent AF often is dictated by the issues of safety and side effects.
Ventricular proarrhythmia from class IA agents (quinidine, procainamide, disopyramide) and class III agents (sotalol, dofetilide, drone-darone, amiodarone) is manifested as QT prolongation and polymorphic ventricular tachycardia (torsades de pointes). Risk factors for this type of proarrhythmia include female gender, left ventricular dysfunction, and hypokalemia.The risk of torsades de pointes appears to be much lower with dronedarone and amiodarone than with the other class Ill drugs.The ventricular proarrhythmia from class IC agents (flecainide and propafenone) is manifested as monomorphic ventricular tachycardia, sometimes associated with widening of the QRS complex during sinus rhythm but not QT prolongation. Published studies indicate that the drugs most likely to result in ventricular proarrhythmia are quinidine, fiecainide, sotalol, and dofetilide. In controlled studies, these agents increased the risk of ventricular tachycardia by a factor of 2 to 6.
Adverse drug events resulting in discontinuation of drug therapy are fairly common with rhythm-control drugs.Withdrawal due to adverse effects was most common with quinidine, disopyramide, flecainide,sotalol, and amiodarone.29 A review of studies in which 32 treatment arms received an antiarrhythmic drug for AF found that 10.4% of patients discontinued drug therapy because of an adverse drug event,most commonly gastrointestinal side effects and neuropathy.
The best options for drug therapy to suppress AF depend on the patient's comorbidities. In patients with lone AF or minimal heart disease (e.g., mild left ventricular hypertrophy), flecainide, propafenone, sotalol, and dronedarone are reasonable first-line drugs, and amiodarone and dofetilide can be considered if the first-line agents are ineffective or not tolerated. In patients with substantial left ventricular hypertrophy (left ventricutar wall thickness >13 mm), the hypertrophy may heighten the risk of ventricular proarrhythmia, and the safest choice for drug therapy is amiodarone. In patients with coronary artery disease, several of the class I drugs have been found toincrease the risk of death, and the safest first-line options are dofetilide, sotalol, and dronedarone, with amiodarone reserved for use asa second-line agent. In patients with heart failure, several antiarrhythmic drugs have been associated with increased mortality,and the onlytwo drugs known to have a neutral effect on survival are amiodaroroneand dofetilide (see Chap. 37).
